![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
FRIDAY, March 21, 2025 -- Loosening restrictions on short-term limited duration...
FRIDAY, March 21, 2025 -- In a clinical guideline issued by the American Colleg...
At its GTC conference in San Jose, Nvidia outlined collaborations with several m...
Bispecific antibodies are revolutionizing targeted therapies, enabling dual-targ...
Today in "The Readout" newsletter: Alnylam's Amvuttra enters ATTR-CM drug race, ...
Following big announcements from Lilly and Merck, J&J is pledging $55 billion ov...
The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adap...
A panel of CDC advisers, who had originally been set to meet in February, will d...
A Big Pharma may seem like an incongruous choice of sponsor for a global music c...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Initially, Amvuttra’s annual list price will be nearly double the yearly cost of...
Johnson & Johnson will invest $55 billion in the U.S. over the next four years. ...
Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressin...
As the U.S. cuts federal research funding and infrastructure, European countries...
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib,...
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, D...
Human medicines European public assessment report (EPAR): Buvidal, buprenorphine...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ul...
"Eric Green, M.D. Ph.D., is no longer serving as director of NIH’s National Huma...